Dr. Ailawadhi's presentation highlighted results from 19 patients with relapsed/refractory multiple myeloma from Cellectar’s Phase 1 and Phase 2 CLOVER-1 trial collected prior to July 30, 2019. The data from the oral presentation support prior literature and preclinical data showing that fractionated dosing provides an enhancement of efficacy and safety while reducing adverse events.

• The patients presented received one of 3 dose levels: a single bolus dose of 31.25 mCi/m² or a fractionated dose of 31.25 mCi/m² or a higher fractionated dose of 37.5 mCi/m² of CLR 131.
• The fractionated 37.5 mCi/m² dose of CLR 131 represents the greatest amount of drug administered to date in the Phase 2 CLOVER-1 trial.
• The overall response rate (ORR) for all multiple myeloma patients across the 3 dose cohorts was 31.3% and a 100% disease control rate.
• Patients receiving the higher fractionated 37.5 mCi/m² dose demonstrated a 50% ORR with the remaining 50% having minimal responses (greater than a 25% reduction in the surrogate marker of efficacy).